Market Overview

BMO Smells Opportunity In OptiNose

BMO Smells Opportunity In OptiNose

Wall Street firms have given rave reviews for OptiNose Inc (NASDAQ: OPTN), which IPO-ed recently.

BMO Capital Markets was no exception, assigning its top rating to shares of the company.

The Analyst

BMO issued its initiation note on OptiNose on Tuesday, with Gary Nachman being the lead analyst.

The Rating

BMO initiated OptiNose with an Outperform and $29 price target. 

The Thesis

OptiNose's exhalation delivery system, or EDS, which is focused on high and deep intranasal deposition of a drug, offers significant improvement over current nasal sprays and aerosols, Nachman said. (See Nachman's track record here.)

The company's lead product Xhance was recently approved for nasal polyps, with a launch planned for the second quarter of 2018, the analyst said. 

Positive feedback from physicians supports the significant opportunity for Xhance, Nachman said. Expanding Xhance to broader chronic sinusitis, or CS, would expand the opportunity further, the analyst said. BMO estimates peak sales of about $700 million for Xhance.

BMO also sees opportunities outside of the ENT/allergy sector, including the potential for "nose-to-brain" delivery of drugs treating certain CNS conditions. This, coupled with the company being a potential M&A target, represents upside to the stock, Nachman said. 

Price Action

OptiNose shares were sliding 6.70 percent to $19.37. Having recorded a listing gain of 19 percent on its Oct. 13 debut,  the stock has been trending broadly higher since then.

Related Link: 

CarGurus, Hair Transplant Firm Among This Week's IPOs

Photo Courtesy Of OptiNose.

Latest Ratings for OPTN

Mar 2020Cantor FitzgeraldReiteratesOverweight
Dec 2019Cowen & Co.Initiates Coverage OnOutperform
Aug 2019BMO CapitalMaintainsOutperform

View More Analyst Ratings for OPTN
View the Latest Analyst Ratings


Related Articles (OPTN)

View Comments and Join the Discussion!

Posted-In: BMO Capital Markets Gary NachmanAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

WKHSRoth CapitalMaintains15.0
HCKTRoth CapitalMaintains22.0
ARECRoth CapitalInitiates Coverage On7.5
SLABWells FargoMaintains180.0
PENWells FargoMaintains310.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at